Category PSMA Therapy in Metastatic prostate

Lu-177-PSMA treatment for metastasized prostate disease

At the Department of Nuclear Medicine of LMU Munich, the purported radio-ligand treatment (RLT) with Lutetium-177 (Lu-177) checked PSMA rivals is offered for patients with metastasized prostate malignant growth. The treatment is an individualized treatment. It is the use of a compelling, however not yet an endorsed, treatment for individual cases. It might be connected

Read More

Lu-177-PSMA treatment for metastasized prostate malignancy

Treatment method of activity By and large, destructive cells from the prostate bear the prostate explicit film antigen (PSMA) on the cell surface. This film antigen fills in as an objective for specific peptides, supposed PSMA ligands (PSMA-DKFZ-617), which can been radiolabeled with the restoratively viable beta producer Lu-177 (Lu-177-PSMA-DKFZ-617). A schematic delineation of a

Read More